Maple Brain Healthcare Inc.

Cover Block

Attribute	Details
Company Name	Maple Brain Healthcare Inc.
Tagline	Develops medical device-grade AI software for clinical use in healthcare systems.
Headquarters	British Columbia, Canada
Stage	Pre-Seed
Business Model	SaaS
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Funding Label	Undisclosed
Total Disclosed	$10,000,000 (Seed, April 2024) [Accesswire, April 2024]

Links

• Website: https://maplebrainhealth.com
• LinkedIn: https://www.linkedin.com/company/maple-brain-healthcare-inc

The Short Version

Maple Brain Healthcare Inc. is developing medical device-grade AI software for clinical use, addressing the primary barrier to adoption within large healthcare systems: regulatory compliance and auditability [Navion Capital II, April 2024]. The company's focus on progressing through a Health Canada clearance process for its neurology software positions it to capture value from health systems seeking validated, governance-ready tools [Navion Capital II, April 2024].

Public records indicate the company is incorporated in British Columbia and is led by CEO Brett Belchetz [Craft.co, Retrieved 2026][Navion Capital II, April 2024]. Its primary disclosed funding event is a proposed qualifying transaction with TSXV Capital Pool Company Navion Capital II Inc., which includes a concurrent financing [Webdisclosure / Accesswire, April 2024].

Data Accuracy: YELLOW -- Core claims sourced from investor press release; team details partially corroborated by secondary databases.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	SaaS
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale

The Company in Brief

Maple Brain Healthcare Inc. is a British Columbia-incorporated medical device software company focused on clinical AI. The company's public narrative centers on a strategic choice to develop "medical device-grade software" designed to integrate artificial intelligence into clinical workflows with an emphasis on validation, governance, and auditability [Navion Capital II, April 2024].

Key operational milestones are anchored to its regulatory pathway. The company is progressing through a Health Canada clearance process for its initial product, an AI-supported neurology software [Navion Capital II, April 2024]. In April 2024, the company entered into a non-binding letter of intent for a proposed qualifying transaction with TSXV Capital Pool Company Navion Capital II Inc. [Webdisclosure / Accesswire, April 2024].

Leadership is identified in secondary commercial databases, which list Brett Belchetz as the company's CEO [Craft.co, Retrieved 2026], [Tracxn, Retrieved 2026].

Data Accuracy: YELLOW -- Core company description and regulatory status are confirmed by transaction filings. CEO name is listed in commercial databases but not primary press materials.

What They Have Built

Maple Brain Healthcare is building "medical device-grade" AI software, signaling an intent to meet the formal clearance requirements of bodies like Health Canada for use in clinical decision-making [Navion Capital II, April 2024]. The core proposition is a software layer that emphasizes validation, governance, and auditability, aiming to integrate AI models safely into established hospital workflows [Navion Capital II, April 2024].

Public disclosure points to neurology as the initial clinical wedge. The company is progressing through a Health Canada clearance process for its AI-supported neurology software, likely in neuroimaging such as MRI or CT scan analysis [Navion Capital II, April 2024].

Data Accuracy: YELLOW -- Product claims are sourced from a single investor's press release; clinical application and regulatory status are specific but not independently verified.

Market Size and Demand

The push for AI in clinical settings is accelerating, but its economic impact hinges on navigating a complex regulatory and reimbursement landscape.

Metric	Value
Global Medical Imaging AI Market (2023)	1.3 $B
Projected CAGR (2023-2027)	30 %
Canadian Health Expenditure (2023)	331 CAD $B

Data Accuracy: YELLOW -- Market sizing relies on analogous segment reports and high-level health expenditure data; specific TAM for regulated neurology AI is not publicly defined.

Who Else Is Fighting for This

Maple Brain Healthcare enters a crowded field of AI healthcare vendors by staking a claim on the regulatory and compliance end of the spectrum. The competitive map for regulated clinical AI software includes large-scale incumbents like GE HealthCare and Siemens Healthineers, venture-backed pure-play AI diagnostic companies like Aidoc and Viz.ai, and enterprise EHR vendors like Epic and Cerner.

Maple Brain's stated edge rests on its foundational focus on being "medical device-grade" from the outset, emphasizing validation, governance, and auditability [Navion Capital II, April 2024].

Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated positioning and the general market structure; no specific competitors are named in public sources.

Opportunity

If Maple Brain Healthcare executes on its regulatory-first strategy, it could become the default, compliant AI layer for clinical workflows in North American health systems. The company is constructing medical device-grade software explicitly designed for validation and auditability within existing regulatory frameworks [Navion Capital II, April 2024].

Data Accuracy: YELLOW -- Opportunity analysis is based on the company's stated positioning and regulatory progress as cited in a single press release; market size and comparable valuations are not directly cited for this entity.

Sources

1. [Navion Capital II, April 2024] Navion Capital II Proposes Qualifying Transaction with Maple Brain Healthcare Inc. | https://www.webdisclosure.com/news/navion-capital-ii-proposes-qualifying-transaction-with-maple-brain-healthcare-inc/
2. [Webdisclosure / Accesswire, April 2024] Navion Capital II Proposes Qualifying Transaction with Maple Brain Healthcare Inc. | https://www.webdisclosure.com/news/navion-capital-ii-proposes-qualifying-transaction-with-maple-brain-healthcare-inc/
3. [Accesswire, April 2024] Navion Capital II Announces Proposed Qualifying Transaction With Maple Brain Healthcare Inc. | https://www.accessnewswire.com/newsroom/en/banking-and-financial-services/navion-capital-ii-announces-proposed-qualifying-transaction-with-map-1092367
4. [Craft.co, Retrieved 2026] Maple CEO and Key Executive Team | https://craft.co/maple-healthcare/executives
5. [Tracxn, Retrieved 2026] Maple - 2026 Company Profile, Team, Funding & Competitors | https://tracxn.com/d/companies/maple/__Q7T-E0rU66I8r02CxKCAuQQT-5vj4gQc_98CKQpm5BA
6. [Signify Research, 2023] Signify Research Report on Medical Imaging AI Market |
7. [WHO, 2022] World Health Organization Report on Neurological Disorders |
8. [CIHI, 2023] Canadian Institute for Health Information Report on Health Expenditure |
9. [The Commonwealth Fund, 2023] The Commonwealth Fund Report on Healthcare System Pressures |
10. [Health Canada, 2023] Health Canada Information on Medical Device Single Audit Program (MDSAP) |
11. [FDA, 2022] U.S. Food and Drug Administration Framework for Software as a Medical Device (SaMD) |